Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL-1706 plus chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy for locally advanced rectal cancer
ChiCTR2500106312Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in rectal adenocarcinoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Complete Remission (CR). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500106312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106312.